

Dietary resistant starch from peas for healthy glu

Submission date 11/03/2015	Recruitment status Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 12/03/2015	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 22/03/2024	Condition category Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

The hormone insulin is produced by β -cells in part of the pancreas known as the Islet of Langerhans. These β -cells can deteriorate and fail to release insulin due to age and lifestyle factors which can lead to the development of type 2 diabetes. Resistant starches are found within certain food products, particularly fruits, vegetables and whole grains, and are believed to be beneficial to β -cells. This is because the resistant starch is not digested and is instead used by bacteria within the gut. The bacteria ferment the resistant starch to produce short chain fatty acids (SCFAs), which are believed to improve β -cell function. We are investigating the effects of food products containing resistant starches found naturally in peas. The aim of this study is to see if resistant starch from peas can improve β -cell function.

Who can participate?

Patients aged 18-65 years with body mass index (BMI) of 20-35 kg/m²

What does the study involve?

Participants first meet one of the research doctors who interview them and conduct a general physical examination. Participants then undergo two separate 28-day dietary supplementation periods in a random order. In each supplementation period participants are provided with common food products (bread, soup, yoghurt, fruit juice, biscuit bars) supplemented with resistant starches or food products with no supplementation. Participants are asked to eat these food products in addition to their normal diet for 28 days. Before and at the end of each 28-day supplementation period participants attend two study visits on consecutive days at the Clinical Investigation Unit, Hammersmith Hospital to assess their β -cell function and insulin sensitivity. There is a break of 28 days between finishing the first dietary supplementation period and starting the second supplementation period.

What are the possible benefits and risks of participating?

Some of the procedures in this study, such as the recording of your weight, height and blood pressure, present no risk. Other procedures, such as taking blood samples, can cause mild discomfort. The risks of taking a blood sample include: slight discomfort when the needle is inserted and possible bruising and a localised infection. These procedures will only be carried out by experienced doctors under aseptic conditions to minimise all these risks. There are no major side effects associated with eating foods containing resistant starch; however, some people may experience mild abdominal bloating.

Where is the study run from?
Imperial College of Science, Technology and Medicine (UK)

When is the study starting and how long is it expected to run for?
April 2015 to September 2026

Who is funding the study?
Biotechnology and Biological Sciences Research Council (UK)

Who is the main contact?
Dr Katerina Petropoulou, katerina.petropoulou12@imperial.ac.uk

Contact information

Type(s)
Scientific

Contact name
Dr Katerina Petropoulou

Contact details
Imperial College of Science, Technology and Medicine
Du Cane Road
London
United Kingdom
W12 0NN
+44 (0) 7428732523
katerina.petropoulou12@imperial.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)
Nil known

Integrated Research Application System (IRAS)
168400

Protocol serial number
CPMS 18551, IRAS 168400

Study information

Scientific Title
Dietary resistant starch from peas for healthy glucose homeostasis: a randomised controlled trial

Acronym
CRESTAR

Study objectives

The aim of this trial is to develop a systematic basis for increasing the intake of resistant starch in the diet in order to protect the function of insulin-secreting pancreatic beta-cells and improve blood glucose homeostasis in an ageing population.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 17/02/2015, London - Surrey Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; Tel: not applicable; surrey.rec@hra.nhs.uk), ref: 15/LO/0184

Study design

Randomized; Interventional; Design type: Treatment

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: Metabolic and endocrine disorders; Subtopic: Metabolic and Endocrine (all Subtopics); Disease: Metabolic & Endocrine (not diabetes)

Interventions

Added 04/07/2016:

Our study will focus on peas, as there is a range of naturally occurring variants known to contain different types of resistant starch. Participants will be provided with normal peas (control) or peas with high resistant starch content (intervention) to add to their diets for 28 days.

Intervention Type

Supplement

Primary outcome(s)

Current primary outcome measures as of 04/07/2016:

Beta-cell function assessed by intravenous glucose tolerance test pre- and post 28 day intervention

Previous primary outcome measures:

Improvement in insulin sensitivity; Timepoint(s): 3 years

Key secondary outcome(s)

Added 04/07/2016:

1. Glucose and insulin responses assessed by meal tolerance test pre- and post 28 day intervention
2. Gastric emptying assessed by ¹³C octanoic breath test pre- and post 28 day intervention
3. Gut microbiota composition assessed from a stool sample pre- and post 28 day intervention

Completion date

01/09/2026

Eligibility

Key inclusion criteria

1. Body mass index (BMI) of 20-35 kg/m²
2. Age between 18-65 years (inclusive)

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

65 years

Sex

All

Key exclusion criteria

1. Weight change of = 3kg in the preceding 2 months
2. Current smokers
3. Substance abuse
4. Excess alcohol intake
5. Pregnancy
6. Diabetes
7. Cardiovascular disease
8. Cancer
9. Gastrointestinal disease e.g. inflammatory bowel disease or irritable bowel syndrome
10. Kidney disease
11. Liver disease
12. Pancreatitis
13. Use of medications likely to interfere with energy metabolism, appetite regulation and hormonal balance, including: anti-inflammatory drugs or steroids, antibiotics, androgens, phenytoin, erythromycin or thyroid hormones.

Date of first enrolment

01/04/2015

Date of final enrolment

01/06/2026

Locations

Countries of recruitment

United Kingdom

England

Study participating centre
Imperial College of Science, Technology and Medicine
Du Cane Road
London
United Kingdom
W12 0NN

Sponsor information

Organisation
Imperial College London (UK)

ROR
<https://ror.org/041kmwe10>

Funder(s)

Funder type
Government

Funder Name
Biotechnology and Biological Sciences Research Council

Alternative Name(s)
UKRI - Biotechnology And Biological Sciences Research Council, Agricultural and Food Research Council, Biotechnology & Biological Sciences Research Council, BBSRC, BBSRC UK, AFRC

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from Katerina Petropoulou (katerina.petropoulou12@imperial.ac.uk).

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No
Other publications		26/10/2020	22/03/2024	Yes	No